Streetbeat News

Analyst Ratings

LIFE

In the last 3 months, 7 analysts have offered 12-month price targets for aTyr Pharma (NASDAQ:LIFE), with an average price target of $21.29, up 46.83% from the previous average of $14.50. The company has received 3 bullish and 4 somewhat bullish ratings.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 8:02 pm

PERI

Over the past 3 months, 7 analysts have published their opinion on Perion Network (NASDAQ:PERI) stock, with 4 bullish, 2 somewhat bullish, and 1 indifferent. The average 12-month price target is $40.71, with a high of $42.00 and a low of $36.00.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 8:01 pm

RAIN

In the last quarter, Rain Oncology (NASDAQ:RAIN) received 4 bullish, 1 somewhat bullish, and 3 indifferent analyst ratings. The company has an average 12-month price target of $10.91, representing a 35.82% decrease from the previous average of $17.00.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 8:00 pm

INTC

A whale investor has taken a bearish stance on Intel (NASDAQ:INTC), with 58% of detected trades having bearish expectations. Whales have been targeting a price range of $15.0 to $37.5 for Intel over the last 3 months. Intel's stock price is down 2.3% at $29.59, and RSI indicators suggest it may be approaching overbought.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 7:46 pm

SQ

A large bullish position on Block (NYSE:SQ) has been spotted, with 61% of big-money traders being bullish and 38% bearish. The price target for Block ranges from $35 to $65 over the last 3 months. Several financial institutions maintain positive ratings on Block, with price targets up to $95.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 7:16 pm

ABBV

A whale has taken a bearish stance on AbbVie (NYSE:ABBV), with 53% of detected unusual options trades being bearish. Whales have been targeting a price range of $110 to $155 for AbbVie over the last 3 months. The stock is currently down 1.55% at $142.65, and RSI indicators suggest it may be oversold. Guggenheim, Wells Fargo, and Morgan Stanley maintain Buy, Overweight, and Overweight ratings on AbbVie, with price targets of $171, $195, and $182, respectively.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 7:16 pm

GHL

MFG

JMP Securities analyst Devin Ryan downgraded Greenhill & Co Inc (GHL) to Market Perform from Market Outperform after the announcement of its acquisition by Mizuho Financial Group Inc (MFG) for $15 per share. The deal, valued at $550 million, is expected to close by year-end. Ryan sees the deal price as fair and estimates revenues of $293.9 million and EPS of $0.45 in 2023, and $355.5 million and $2.15 in 2024.

Portfolio Pulse from Lekha Gupta

May 23, 2023 | 7:15 pm

BPMC

Blueprint Medicines Corporation (NASDAQ:BPMC) received FDA approval for Ayvakit, the first and only treatment for indolent systemic mastocytosis. Analysts from Needham, HC Wainwright, Wedbush, and Barclays have raised their price targets for BPMC, with optimism about Ayvakit's future sales and growth potential.

Portfolio Pulse from Vandana Singh

May 23, 2023 | 7:06 pm

PANW

Over the past 3 months, 11 analysts have published their opinion on Palo Alto Networks (NASDAQ:PANW) stock, with an average 12-month price target of $234.27. The current average has increased by 6.73% from the previous average price target of $219.50.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 7:06 pm

CELH

In the last 3 months, 11 analysts have provided 12-month price targets for Celsius Holdings (NASDAQ:CELH), with an average price target of $125.36, up 8.77% from the previous average of $115.25. The company has received 5 bullish and 6 somewhat bullish ratings.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 7:05 pm